Valuation: Ryvu Therapeutics S.A.

Market Cap 361M 92.84M 82.46M 77.11M 70.27M 132M 8.94B 134M 933M 4.55B 349M 341M 14.62B P/E 2026 *
-8.31x
P/E 2027 * 6.4x
Enterprise Value 367M 94.38M 83.83M 78.4M 71.44M 134M 9.09B 136M 948M 4.63B 354M 347M 14.86B EV / Sales 2026 *
3.99x
EV / Sales 2027 * 2.45x
Free-Float
64.97%
Yield 2026 *
-
Yield 2027 * -
1 day-0.13%
1 week-1.88%
Current month-0.13%
1 month-10.13%
3 months+11.89%
6 months-32.09%
Current year-42.36%
1 week 15.54
Extreme 15.54
16.14
1 month 15.54
Extreme 15.54
18.42
Current year 13.64
Extreme 13.64
28.95
1 year 13.64
Extreme 13.64
31.9
3 years 13.64
Extreme 13.64
72.4
5 years 13.64
Extreme 13.64
72.4
10 years 13.64
Extreme 13.64
78
Manager TitleAgeSince
Chief Executive Officer - 2006-12-31
Chief Tech/Sci/R&D Officer - 2022-01-31
Chief Operating Officer 41 2020-11-22
Director TitleAgeSince
Chairman - 2018-12-31
Director/Board Member 75 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
4/15/26 Sell

Executive/Senior Manager

2,500 0.0108%
4/15/26 Sell

Executive/Senior Manager

5,000 0.0216%
4/15/26 Sell

Executive/Senior Manager

5,000 0.0216%
Change 5-day change 1-year change 3-year change Capi.($)
-0.13%-1.88%-44.21%-76.04% 94.13M
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
-3.21%+2.36%+28.92%+22.05% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average -0.85%-0.19%+43.39%+131.17% 39.69B
Weighted average by Cap. -0.42%+0.11%+57.75%+145.67%

Financials

2026 *2027 *
Net sales 92M 23.65M 21.01M 19.64M 17.9M 33.7M 2.28B 34.17M 238M 1.16B 88.8M 86.87M 3.72B 134M 34.35M 30.51M 28.54M 26M 48.95M 3.31B 49.63M 345M 1.68B 129M 126M 5.41B
Net income -48M -12.34M -10.96M -10.25M -9.34M -17.58M -1.19B -17.83M -124M -605M -46.33M -45.32M -1.94B 7.3M 1.88M 1.67M 1.56M 1.42M 2.67M 181M 2.71M 18.86M 92.02M 7.05M 6.89M 296M
Net Debt 6M 1.54M 1.37M 1.28M 1.17M 2.2M 149M 2.23M 15.5M 75.63M 5.79M 5.67M 243M -34M -8.74M -7.76M -7.26M -6.62M -12.46M -842M -12.63M -87.83M -429M -32.82M -32.11M -1.38B
Logo Ryvu Therapeutics S.A.
Ryvu Therapeutics SA is a Poland-based company that operates in the biotechnology industry. The Company focuses on oncology drug discovery and research and development (R&D) activities. Its primary products are therapeutic drug candidates and related research programs for cancer treatment. These products are biotechnology based therapies and drug development assets that are evaluated and advanced through preclinical and clinical research. The primary goal of this technology is to identify therapeutic targets and support the development of medicines for patients with cancer. The Company also conducts contract research activities and enters licensing and research collaboration agreements related to biotechnology and drug development.
Employees
228
Date Price Change Volume
26-10-01 PLN 15.62 -0.13% 7,133
26-09-30 PLN 15.64 -1.64% 7,803
26-09-29 PLN 15.90 -1.12% 8,372
26-09-28 PLN 16.08 +0.88% 9,037
26-09-25 PLN 15.94 +0.13% 8,764
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
15.62PLN
Average target price
29.90PLN
Spread / Average Target
+91.42%

Quarterly revenue - Rate of surprise